1. Home
  2. PROV vs IFRX Comparison

PROV vs IFRX Comparison

Compare PROV & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROV
  • IFRX
  • Stock Information
  • Founded
  • PROV 1956
  • IFRX 2007
  • Country
  • PROV United States
  • IFRX Germany
  • Employees
  • PROV N/A
  • IFRX N/A
  • Industry
  • PROV Savings Institutions
  • IFRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PROV Finance
  • IFRX Health Care
  • Exchange
  • PROV Nasdaq
  • IFRX Nasdaq
  • Market Cap
  • PROV 102.0M
  • IFRX 86.0M
  • IPO Year
  • PROV 1996
  • IFRX 2017
  • Fundamental
  • Price
  • PROV $15.59
  • IFRX $1.29
  • Analyst Decision
  • PROV Hold
  • IFRX Strong Buy
  • Analyst Count
  • PROV 2
  • IFRX 5
  • Target Price
  • PROV $16.25
  • IFRX $9.80
  • AVG Volume (30 Days)
  • PROV 5.0K
  • IFRX 7.5M
  • Earning Date
  • PROV 10-28-2025
  • IFRX 11-07-2025
  • Dividend Yield
  • PROV 3.61%
  • IFRX N/A
  • EPS Growth
  • PROV N/A
  • IFRX N/A
  • EPS
  • PROV 0.90
  • IFRX N/A
  • Revenue
  • PROV $39,823,000.00
  • IFRX $73,729.00
  • Revenue This Year
  • PROV $4.14
  • IFRX N/A
  • Revenue Next Year
  • PROV $3.70
  • IFRX $1,216.24
  • P/E Ratio
  • PROV $17.26
  • IFRX N/A
  • Revenue Growth
  • PROV 0.07
  • IFRX N/A
  • 52 Week Low
  • PROV $12.98
  • IFRX $0.71
  • 52 Week High
  • PROV $16.70
  • IFRX $2.82
  • Technical
  • Relative Strength Index (RSI)
  • PROV 51.38
  • IFRX 47.32
  • Support Level
  • PROV $15.03
  • IFRX $1.16
  • Resistance Level
  • PROV $15.69
  • IFRX $1.94
  • Average True Range (ATR)
  • PROV 0.24
  • IFRX 0.22
  • MACD
  • PROV -0.01
  • IFRX 0.00
  • Stochastic Oscillator
  • PROV 58.95
  • IFRX 16.03

About PROV Provident Financial Holdings Inc.

Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: